MX2018000984A - Terapias de combinacion. - Google Patents

Terapias de combinacion.

Info

Publication number
MX2018000984A
MX2018000984A MX2018000984A MX2018000984A MX2018000984A MX 2018000984 A MX2018000984 A MX 2018000984A MX 2018000984 A MX2018000984 A MX 2018000984A MX 2018000984 A MX2018000984 A MX 2018000984A MX 2018000984 A MX2018000984 A MX 2018000984A
Authority
MX
Mexico
Prior art keywords
combination therapies
polypeptide
compositions
treating
subject
Prior art date
Application number
MX2018000984A
Other languages
English (en)
Inventor
Gudmundsdóttir Ágústa
Scheving Reynir
Original Assignee
Enzymatica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymatica Ab filed Critical Enzymatica Ab
Publication of MX2018000984A publication Critical patent/MX2018000984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención proporciona terapias de combinación para uso en el tratamiento de una biopelícula bacteriana en un sujeto que comprende (a) un polipéptido que tiene actividad de serina proteasa y (b) uno o más compuestos antibióticos. También se proporcionan composiciones y métodos de uso de las mismas.
MX2018000984A 2015-07-24 2016-07-22 Terapias de combinacion. MX2018000984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178209.1A EP3120866A1 (en) 2015-07-24 2015-07-24 Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
PCT/EP2016/067570 WO2017017027A1 (en) 2015-07-24 2016-07-22 Combination therapies

Publications (1)

Publication Number Publication Date
MX2018000984A true MX2018000984A (es) 2018-08-09

Family

ID=53785469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000984A MX2018000984A (es) 2015-07-24 2016-07-22 Terapias de combinacion.

Country Status (12)

Country Link
US (1) US11338021B2 (es)
EP (2) EP3120866A1 (es)
JP (1) JP2018521143A (es)
KR (1) KR20180031704A (es)
CN (1) CN107921102B (es)
AU (1) AU2016301021B2 (es)
BR (1) BR112018001391A2 (es)
CA (1) CA2992677A1 (es)
DK (1) DK180380B1 (es)
MX (1) MX2018000984A (es)
RU (1) RU2725800C2 (es)
WO (1) WO2017017027A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
WO2020229521A1 (en) * 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
US20230165776A1 (en) * 2020-05-13 2023-06-01 Zymiq Technology Ab Protease formulation for treatment of microbial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
EP1202743B1 (en) 1999-06-18 2004-10-06 Jon Bragi Bjarnason Pharmaceutical and cosmetic compositions comprising cod serine proteases and their pharmaceutical and cosmetic use
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
CA2780756A1 (en) 2009-11-23 2011-05-26 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
CN104039812A (zh) 2011-05-31 2014-09-10 和黄生物膜医疗解决方案有限公司 细胞聚集体的分散和脱离
CN103007258A (zh) 2011-09-22 2013-04-03 安淇生物控释技术(苏州)有限公司 含鱼丝氨酸蛋白酶和抗菌化合物的医用组合物及其用途
WO2013095439A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Oral care compositions
CN103191491A (zh) 2012-01-10 2013-07-10 查红梅 一种包装物及其用途和制法
RU2646102C2 (ru) 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
CN203090136U (zh) * 2013-02-02 2013-07-31 成都玺汇科技有限公司 一种口鼻两用喷雾器
GB201405784D0 (en) * 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
US20160339087A1 (en) * 2014-01-29 2016-11-24 Enzymatica Ab Novel treatments

Also Published As

Publication number Publication date
EP3325002A1 (en) 2018-05-30
RU2725800C2 (ru) 2020-07-06
WO2017017027A1 (en) 2017-02-02
CA2992677A1 (en) 2017-02-02
DK201870043A1 (en) 2018-02-05
RU2018106490A3 (es) 2020-01-24
CN107921102A (zh) 2018-04-17
KR20180031704A (ko) 2018-03-28
JP2018521143A (ja) 2018-08-02
US20200085921A1 (en) 2020-03-19
AU2016301021A1 (en) 2018-02-01
AU2016301021B2 (en) 2022-11-10
DK180380B1 (en) 2021-03-17
US11338021B2 (en) 2022-05-24
BR112018001391A2 (pt) 2018-09-11
CN107921102B (zh) 2022-09-09
EP3120866A1 (en) 2017-01-25
RU2018106490A (ru) 2019-08-26

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2022004304A (es) Agentes inductores de apoptosis.
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2018003301A (es) Inhibidores de pcna.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
MX2018000984A (es) Terapias de combinacion.
MX2021016050A (es) Formulaciones transdermicas.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
PH12016501838A1 (en) Compounds and their methods of use
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2019013785A (es) Metodos y tratamiento de trauma.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.